Odense University Hospital
Odense, 5000, Denmark
NCT Number: NCT05163405
In the present study, we have trained 10 patients in subcutaneous self-administration of Velcade. After their training, patients will alternately receive their treatment in the hospital and at home by self-administration. In keeping with common practice, a nurse contacts the patients by telephone before 9.00 am on the day of treatment to ensure that the patient is physically "fit" to receive the medication and to discuss any side effects. To highlight the advantages and disadvantages of the changed treatment practice from the perspectives of both patients and healthcare professionals, data is collected from two consecutive semi-structured interviews with n = 10 patients and n = 1 focus group interview of the healthcare professionals involved. Moreover, time registration of medication administration both at the hospital and in the patients' home is done. The qualitative data will be analyzed via the method of condensation and continual quantitative data will form the basis of a cost-benefit analysis.
Looking for future studies?
Notify MeAll sexes
Observational
Odense, 5000, Denmark
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Self-administration of subcutaneously Velcade.
Other names: Velcade
Time frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022
Qualitative interviews with all 10 included patients
Time frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022
Patients and health professionals (including pharmacy staff) registration of time spend on treatment on all 10 included patients.
Time frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022
Focus group interview with healthcare professionals involved in the treatment.
Time frame: Through study completion, from 01. dec. 2019 until 01. jun. 2022
Evaluation of financial savings on home treatment including healthcare salaries and transportation.
Karin B. Ø. Dieperink
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04975555
Acute Lymphoblastic Leukemia, Blood Protein Disorders
Birmingham, Alabama, United States
View Trial DetailsNCT05024045
B-cell Lymphoma, Blood Protein Disorders
Tucson, Arizona, United States
View Trial DetailsNCT01139476
Blood Protein Disorders, Cardiovascular Diseases
Iowa City, Iowa, United States
View Trial DetailsNCT06483139
Acute Kidney Injury, Blood Protein Disorders
Boston, Massachusetts, United States
View Trial Details